A. Rivero‐Juárez

发表

HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy

J. Torre-Cisneros, M. Frias, D. Rodriguez-Cano, 2016, The Pharmacogenomics Journal.

Early Hemoglobin kinetics in response to ribavirin: Safety lesson learned from Hepatitis C to CoVID-19 therapy

M. Frias, Á. Camacho, A. Rivero‐Juárez, 2020, medRxiv.

Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues.

M. Frias, J. Macías, J. Pineda, 2021, The Journal of antimicrobial chemotherapy.

The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities

M. Frias, Á. Camacho, A. Rivero‐Juárez, 2020 .

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype

J. Torre-Cisneros, Á. Camacho, A. Rivero‐Juárez, 2013, AIDS.

HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study

J. Pineda, A. Rivero‐Juárez, M. Ríos, 2017, HIV clinical trials.

Present-day treatment of tuberculosis and latent tuberculosis infection.

A. Rivero‐Juárez, A. Rivero, J. M. Kindelán, 2011, Enfermedades infecciosas y microbiologia clinica.

Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

J. Macías, J. Pineda, A. Rivero‐Juárez, 2018, HIV clinical trials.

The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?

A. Rivero‐Juárez, J. Blanco, A. Rivero-Juarez, 2016, Expert review of anti-infective therapy.

HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance

M. Frias, D. Rodriguez-Cano, B. Manzanares-Martín, 2018, Scientific Reports.

Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C

A. Rivero‐Juárez, A. Rivero, J. Berenguer, 2016, Open forum infectious diseases.

Liver Fibrosis, Host Genetic and Hepatitis C Virus Related Parameters as Predictive Factors of Response to Therapy against Hepatitis C Virus in HIV/HCV Coinfected Patients

A. Rivero‐Juárez, A. Rivero, L. López-Cortés, 2014, PloS one.

Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.

A. Rivero‐Juárez, A. Rivero, A. Rivero-Juarez, 2016, The Lancet. Infectious diseases.

Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

A. Rivero‐Juárez, A. Rivero, L. López-Cortés, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C

F. Cuenca-López, A. Rivero‐Juárez, A. Rivero, 2017, Expert opinion on drug metabolism & toxicology.

Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.

J. Torre-Cisneros, J. Macías, J. Pineda, 2010, The Journal of antimicrobial chemotherapy.

Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients.

M. Frias, A. Rivero‐Juárez, A. Rivero, 2018, Pharmacogenomics.

Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C

M. Frias, A. Rivero‐Juárez, A. Rivero, 2018, Expert opinion on drug metabolism & toxicology.

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection

J. Macías, J. Pineda, A. Rivero‐Juárez, 2015, PloS one.

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

V. Soriano, J. Macías, J. Pineda, 2013, The Journal of infection.

The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients

G. Dolci, G. Guaraldi, L. Real, 2016, PloS one.

Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals

L. Real, M. Frias, J. Macías, 2015, AIDS.

Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis

J. Macías, J. Pineda, A. Rivero‐Juárez, 2017, AIDS.

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection

A. Rivero‐Juárez, A. Rivero, T. Brieva, 2017, Expert opinion on drug metabolism & toxicology.

Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection.

M. Clerici, L. De Gioia, D. Forni, 2014, Molecular biology and evolution.

Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.

J. Macías, J. Pineda, A. Rivero‐Juárez, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.